Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Solasia Pharma KK ( (JP:4597) ) just unveiled an update.
Solasia Pharma K.K. has entered a licensing agreement with Firebird Biologics for the exclusive sales and distribution of DARVIAS and episil across 19 countries in Southeast Asia, Oceania, the Middle East, and Africa. This agreement marks a significant step in Solasia’s expansion strategy, with Firebird Biologics also obtaining sales approval for episil in Singapore, initiating preparations for sales activities, and beginning product supply from Solasia.
More about Solasia Pharma KK
Solasia Pharma K.K. operates in the pharmaceutical industry, focusing on the development and commercialization of oncology drugs and medical devices. The company is headquartered in Tokyo, Japan, and is known for products like the antitumor drug DARVIAS and the medical device episil, which is used for managing oral pain caused by cancer treatments.
Average Trading Volume: 13,641,941
Technical Sentiment Signal: Buy
Current Market Cap: Yen9.97B
For detailed information about 4597 stock, go to TipRanks’ Stock Analysis page.